Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
PaxMedica, Inc. is a biotechnology firm focused on developing treatments for neurodevelopmental disorders, particularly utilizing its proprietary formulation of the anti-parasitic drug, suramin. The company operates primarily in the United States, with ongoing clinical trials aimed at demonstrating the efficacy of its lead candidate in treating conditions such as autism spectrum disorder.
PaxMedica generates revenue through clinical trials and partnerships aimed at developing its drug candidates. The company has a unique competitive advantage with its focus on repurposing existing drugs, which can reduce development timelines and costs. Its proprietary formulation of suramin is positioned to address unmet medical needs in neurodevelopmental disorders, potentially allowing for premium pricing.
Results from clinical trials for suramin in treating autism spectrum disorder
Regulatory approvals from the FDA for new drug applications
Partnership announcements with larger pharmaceutical companies
Market sentiment regarding neurodevelopmental disorder treatments
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Emergence of alternative therapies for neurodevelopmental disorders
Increased competition from larger biotech firms with more resources
High cash burn rate due to ongoing clinical trials
Dependency on future funding rounds to sustain operations
low - The demand for healthcare and biotechnology products is relatively inelastic, less influenced by economic cycles.
Moderate - Rising interest rates could increase the cost of capital for clinical trials and R&D, potentially delaying development timelines and impacting valuations.
minimal - The company has no debt, reducing its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant volatility, with a 600% return over the past year.